STENOCARE A/S NASDAQ FIRST NORTH GROWTH MARKET, DENMARK TICKER: STENO
STENOCARE has a strategy to become a leading European brand within prescription-based medical cannabis. So far, 18 European countries have legalized medical cannabis and more countries are debating and planning to legalise in the coming years. Since 1961, cannabis has been classified as one the most dangerous drugs in the world. This has prevented companies from research & development and/or to produce medical cannabis products, and even countries could not easily legalise it for treatment of patient.
This week the United Nations (U.N.) decided to remove medical cannabis from the category of the most dangerous drugs (like heroin). This reclassification will not make medical cannabis legal for general use, but it is expected that it will have a positive impact on more research and increased use in treatment of patients. Also, many countries look for guidance from the U.N. in their work to legalize medical cannabis and therefore this reclassification can further accelerate global legalization of medical cannabis.
Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments:
“Since the passing of the U.N. Single Convention on Narcotic Drugs in 1961, medical cannabis research and treatment has been stigmatized. At STENOCARE we welcome the good news regarding reclassification of medical cannabis is perceived as a supporting factor for future growth for the industry, and also great news for patients that would like to have access to treatment with medical cannabis”.
Read more about the decision on New York Times: https://www.nytimes.com/2020/12/02/world/europe/cannabis-united-nations-drug-policy.html